Key portfolio assets
| Compound | Mechanism of action | Target indication | Status | More Information |
|
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, Sweden, and Finland; approved throughout the EU | |
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
New data and evaluation of long-term treatment with lucerastat supportive further investigation – regulatory pathway to be discussed with the FDA | |
| Daridorexant | Dual orexin receptor antagonist | Pediatric insomnia | Phase 2 in pediatric insomnia ongoing | |
| IDOR-1117-2520 | CCR6 receptor antagonist | Psoriasis | Proof-of-concept study in preparation | |
|
ACT-1004-1239 |
CXCR7 / ACKR3 receptor antagonist | Progressive multiple sclerosis | Proof-of-concept study in preparation | |
| ACT-777991 | CXCR3 antagonist | Vitiligo | Proof-of-concept study in preparation |
| Synthetic Glycan Vaccine Platform | Idorsia will seek a partner for the platform or individual vaccines | ||
| IDOR-1134-2831 | Synthetic glycan vaccine | Clostridioides difficile infection | Initial Phase 1 data showing safety and immunogenicity |
For more information about our portfolio please read our Innovation fact sheet.